Gumitide

Gumitide is a South Korean biotechnology company specializing in the development of functional peptide therapeutics for dermatological and regenerative medicine indications. The company leverages its proprietary peptide platform to create treatments that effectively penetrate the skin barrier to modulate intracellular signaling. Its lead candidate, GT-002, is a novel peptide designed to treat androgenetic alopecia by activating the Wnt/beta-catenin signaling pathway to promote hair follicle regeneration. Gumitide is also expanding its pipeline to include programs for skin rejuvenation and wound healing. The company is currently advancing its lead programs through clinical development in South Korea following successful preclinical validation.